Roche Forges Ahead With Taspoglutide Despite Cancer Signal With Competitor GLP-1
Roche expects Phase III data on the type 2 diabetes drug to be available by the end of the year and maintains that any carcinogenicity issue is rodent-specific.
Roche expects Phase III data on the type 2 diabetes drug to be available by the end of the year and maintains that any carcinogenicity issue is rodent-specific.